Material Balance of [14C]Zorifertinib in Healthy Adult Males

Phase 1, open-label, single-arm trial of zorifertinib in non-small cell lung cancer (NSCLC), sponsored by Alpha Biopharma. Primary endpoints: Total radioactive recovery and cumulative total radioactive recovery in urine and feces up to 312 hours, Percentage of total radioactivity exposure (%AUC), percentage of parent drug and its metabolites (%Dose), and metabolite identification up to 312 hours and 9 more. Started Jul 2026; status: completed.